Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

References

• Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pozzoni P, Tentori F, del Vecchio L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 2003;18:vii2–9
   PubMedGoogle Scholar
• Zoccali C. Cardiovascular risk in uraemic patients – is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454–457
   PubMed Web of Science ®Google Scholar
• Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol. 2012;2012:691369
   PubMedGoogle Scholar
• Stenvinkel P, Herzog CA. Cardiovascular disease in chronic kidney disease. In Floege J, Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. 4th ed. Missouri: Elsevier Saunders; 2010:935–950
   Google Scholar
• Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010:535918
   PubMed Web of Science ®Google Scholar
• Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110:3335–3340
   PubMed Web of Science ®Google Scholar
• Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34:307–310
   PubMed Web of Science ®Google Scholar
• Hansen T, Ahlström H, Söderberg S, et al. Visceral adipose tissue, adiponectin levels and insulin resistance are related to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly population. Atherosclerosis. 2009;205:163–167
   PubMed Web of Science ®Google Scholar
• Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290:E1253–E1261
   PubMed Web of Science ®Google Scholar
• Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol. 2012;686:116–123
   PubMed Web of Science ®Google Scholar
• Xie H, Xie PL, Wu XP, et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res. 2011;92:296–306
   Google Scholar
• Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012;4:37
   PubMed Web of Science ®Google Scholar
• Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011;12:60
   PubMed Web of Science ®Google Scholar
• de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56:1655–1661
   PubMed Web of Science ®Google Scholar
• Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010;88:29–33
   PubMed Web of Science ®Google Scholar
• Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008;57:801–808
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity. 2011;19:1552–1559
   PubMed Web of Science ®Google Scholar
• El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischemic heart disease. Diabet Med. 2011;28:1194–1200
   PubMed Web of Science ®Google Scholar
• Yoo HJ, Hwang SY, Hong HC, et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011;10:103
   PubMed Web of Science ®Google Scholar
• Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011;93:21–25
   PubMed Web of Science ®Google Scholar
• Zhong X, Zhang HY, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32:873–878
   PubMed Web of Science ®Google Scholar
• Shibata R, Takahashi R, Kataoka Y, et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res. 2011;34:1309–1312
   PubMed Web of Science ®Google Scholar
• Alcelik A, Tosun M, Ozlu MF, et al. Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press Res. 2012;35:511–516
   Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64–S71
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
   PubMed Web of Science ®Google Scholar
• Kablak-Ziembicka A, Przewlocki T, Tracz W, et al. Prognostic value of carotid intima-media thickness in detection of coronary atherosclerosis in patients with calcified aortic valve stenosis. J Ultrasound Med. 2005;24:461–467
   Google Scholar
• Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393:668–672
   PubMed Web of Science ®Google Scholar
• Choi JH, Rhee EJ, Kim KH, Woo HY, Lee WY, Sung KC. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur J Endocrinol. 2011;165:789–796
   PubMed Web of Science ®Google Scholar
• Shaker M, Mashhadani ZI, Mehdi AA. Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients. Oman Med J. 2010;25:289–293
   Google Scholar
• Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010;7:27
   PubMed Web of Science ®Google Scholar
• Tan BK, Adya R, Farhatullah S, Chen J, Lehnert H, Randeva HS. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes. 2010;59:3023–3031
   PubMed Web of Science ®Google Scholar
• Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond). 2012;9:36
   Google Scholar
• Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol. 2011;46:91–97
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regul Pept. 2013;182:1–6
   Google Scholar